Viatris is poised for appreciation with new product launches and a stronger balance sheet. Read why VTRS stock is a buy due ...

Canonsburg, Pennsylvania-based Viatris Inc. (VTRS) operates as a pharmaceutical company. It offers prescription brand, ...

Pharmaceutical company Viatris (VTRS 13.52%) reported third-quarter 2024 financial results on Thursday, Nov. 7, that topped ...

On Friday, Viatris Inc (VTRS) stock saw a modest uptick, ending the day at $12.83 which represents a slight increase of $0.21 or 1.66% from the prior close of $12.62. The stock opened at $12.63 and ...

Viatris, Inc. ( (VTRS)) has released its Q3 earnings. Here is a breakdown of the information Viatris, Inc. presented to its investors. Viatris Inc. is a global healthcare company engaged in providing ...

On Friday, Viatris Inc (VTRS) stock saw a decline, ending the day at $12.96 which represents a decrease of $-0.22 or -1.67% from the prior close of $13.18. The stock opened at $13.07 and touched a low ...

Barclays analyst Balaji Prasad raised the firm’s price target on Viatris (VTRS) to $12 from $11 and keeps an Underweight rating on the ...

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsBill Szablewski - Head of Capital ...

Viatris reports Q3 2024 net sales of $3.74 billion, beating estimates. Adjusted EPS at $0.75 surpasses $0.68 consensus. 2024 ...

Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.

Viatris' strong performance is further underscored ... authorities over the next few months and put a development plan together for this. So we expect that Sota will start contributing to our ...